The N-terminus of hTERT contains a DNA-binding domain and is required for telomerase activity and cellular immortalization by Sealey, David C. F. et al.
The N-terminus of hTERT contains a DNA-binding
domain and is required for telomerase activity
and cellular immortalization
David C. F. Sealey
1,2,3, Le Zheng
1,3, Michael A. S. Taboski
1,2,3, Jennifer Cruickshank
2,3,
Mitsuhiko Ikura
1,3 and Lea A. Harrington
1,2,3,4,*
1Department of Medical Biophysics, University of Toronto,
2Campbell Family Institute for Breast Cancer
Research,
3Ontario Cancer Institute, University Health Network, Toronto, Ontario, M5G 2C1, Canada and
4Wellcome Trust Centre for Cell Biology, University of Edinburgh, Edinburgh, EH9 3JR, UK
Received August 6, 2009; Revised November 20, 2009; Accepted November 24, 2009
ABSTRACT
Telomerase defers the onset of telomere
damage-induced signaling and cellular senescence
by adding DNA onto chromosome ends. The ability
of telomerase to elongate single-stranded telomeric
DNA depends on the reverse transcriptase domain
of TERT, and also relies on protein:DNA contacts
outside the active site. We purified the N-terminus
of human TERT (hTEN) from Escherichia coli, and
found that it binds DNA with a preference for
telomeric sequence of a certain length and
register. hTEN interacted with the C-terminus of
hTERT in trans to reconstitute enzymatic activity
in vitro. Mutational analysis of hTEN revealed that
amino acids Y18 and Q169 were required for
telomerase activity in vitro, but not for the interac-
tion with telomere DNA or the C-terminus. These
mutants did not reconstitute telomerase activity in
cells, maintain telomere length, or extend cellular
lifespan. In addition, we found that T116/T117/
S118, while dispensable in vitro, were required for
cellular immortalization. Thus, the interactions of
hTEN with telomere DNA and the C-terminus of
hTERT are functionally separable from the role
of hTEN in telomere elongation activity in vitro
and in vivo, suggesting other roles for the protein
and nucleic acid interactions of hTEN within, and
possibly outside, the telomerase catalytic core.
INTRODUCTION
Telomeres are specialized nucleoprotein structures that
form the ends of linear chromosomes in most eukaryotes.
Telomere DNA, which ranges in length from 100 to
300bp in ciliates and yeasts, 5–15kbp in humans, and
up to 100kbp in mice, is comprised by a short repeating
duplex sequence (50-TTAGGG-30/30-AATCCC-50 in
humans) that terminates in a short G-rich single-stranded
overhang (1). The G-overhang can invade the duplex at an
upstream position to create a large telomeric loop, or
T-loop, in a manner that is facilitated by TRF2 (2,3).
TRF1 and TRF2 homodimers bind to the telomere
duplex and form a platform for other components of the
shelterin complex: RAP1, TIN2, TPP1 and POT1. In
addition to binding TPP1, POT1 interacts with, and reg-
ulates access to the G-overhang (4). TRF2 and POT1
protect the telomere by limiting the activation of ATM
and ATR pathways, respectively, and downstream
end-processing activities that normally accompany the
DNA damage response (5).
Telomeres shorten with every cycle of DNA replication
due to the positioning and degradation of the terminal
RNA primer involved in generating the daughter lagging
strand, and the nucleolytic resection involved in
generating the G-overhang (6–9). Human telomeres
shorten by  100bp/cell division (10). In cells that
undergo many cell divisions, telomeres can reach a
minimum length that elicits a DNA damage response
(11,12). Consequently, cells enter a usually irreversible
non-proliferative state termed senescence. The onset of
senescence can be indeﬁnitely postponed by the mainte-
nance of telomere length by telomerase (see below).
Telomerase, originally discovered in Tetrahymena
thermophila by Greider and Blackburn (13), is a reverse
transcriptase formed by the telomerase reverse
transcriptase (TERT) and the associated telomerase
RNA (TR) which bears the template for synthesis of the
telomeric G-strand (14–19). The mutation of telomerase
components and premature telomere shortening are
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and idiopathic pulmonary ﬁbrosis that may involve the
exhaustion of stem cell compartments (20). In many
human somatic cell types, hTERT is transcriptionally
repressed (15,16,21). In these cells, telomere erosion and
the eventual activation of a DNA damage checkpoint act
as barriers to tumorigenesis (22). In cells capable of
overcoming senescence, further telomere shortening can
result in telomere instability, chromosome end-to-end
fusion and tumorigenic conversion (23). Notably, cancer
cells can divide indeﬁnitely due to the maintenance
of telomeres by the activation of hTERT transcription
and telomerase activity (16,21,24) [in exceptional cases,
telomeres in some cell types can be maintained by the
recombination-based alternative lengthening of telomeres
(ALT) (25)]. As proof of concept, primary cells transduced
with hTERT cDNA gain the ability to maintain telomeres
and divide indeﬁnitely (26,27). Thus, telomerase is an
attractive target for the development of anti-cancer
therapeutics.
The recruitment of telomerase to telomeres is coordina-
ted with DNA replication (28) and is regulated by the
shelterin complex. Telomere length is ‘counted’ by the
complement of telomere duplex binding factors and their
eﬀectors, such that the probability of elongation of a given
telomere is inversely correlated with its length (29–33). In
human cells, POT1 negatively regulates telomerase action
at the telomere by binding directly to, and possibly con-
cealing the 30 DNA terminus (34–37). POT1 may also pos-
itively regulate telomerase action at the telomere; when
positioned on DNA upstream of a 30 end in vitro, POT1
stimulates telomerase activity (36,38).
TERT contains several evolutionarily conserved
domains. Domains in the C-terminal half of hTERT
[amino acids (aa) 601–936] share homology with other
reverse transcriptases and form the active site of the
enzyme (15–17). Domains in the central region of the
protein (CP, QFP, T; aa 397–594) bind the TR (39). A
conserved N-terminal domain (GQ), identiﬁed by multiple
sequence alignment of mammalian, yeast, ciliate and plant
TERT sequences (40), is separated from the CP domain by
a non-conserved region that varies in length between
organisms (39). Telomerase exhibits nucleotide addition
processivity by adding one nucleotide at a time onto the
30-end of a DNA primer, up to the 50-end of the RNA
template. While Saccharomyces cerevisiae telomerase, for
example, has the ability to add only a limited number of
telomeric repeats onto a DNA primer in vitro (41), human
and T. thermophila telomerases exhibit an ability to add
multiple telomeric repeats without dissociating from the
primer (42,43). Observations that the 50-end of the primer
can inﬂuence substrate utilization led to the notion that a
so-called ‘anchor site’ outside of the reverse transcriptase
domain of TERT contacts the DNA primer upstream of
the active site and may facilitate iterative copying and
repositioning of the RNA template (44–49). Mounting
evidence suggests that the N-terminus of TERT contains
this anchor site for DNA (50) that is important for both
telomerase activity and repeat addition processivity.
Indeed, subsequent structural determination of the
N-terminus of T. thermophila TERT revealed a groove
on one side of the domain that may accommodate
single-stranded DNA (51). The domain can form
crosslinks to single-stranded DNA primers, and removal
of the domain or mutation of exposed residues along the
groove reduces primer crosslinking and impairs telomere
DNA elongation in vitro (51–53). The N-termini of
S. cerevisiae and human TERTs also interact with DNA
(40,54,55), and mutations in the region have been
identiﬁed that impair telomerase activity/processivity
and, in some cases, the ability of telomerase to immortal-
ize cells (40,54–63).
In this study, we found that the N-terminus of human
TERT (hTEN), expressed and puriﬁed from bacteria,
exhibited a length- and sequence-dependent aﬃnity for
telomeric DNA in an electrophoretic mobility shift assay
(EMSA). Human TEN also interacted with, and restored
catalytic potential to an hTERT truncation mutant
lacking the N-terminus in trans. We identiﬁed point muta-
tions in hTEN that strongly impaired telomerase activity
and the ability of telomerase to immortalize cells in
culture, but did not impair the interaction with telomeric
DNA or the hTERT C-terminus.
MATERIALS AND METHODS
Expression and puriﬁcation of recombinant hTERT
To express hTERT in E. coli, the DNA sequence encoding
hTERT(aa 1–200) was optimized by correcting for E. coli
codon bias and minimizing mRNA secondary structure
(GenScript Corp.). The custom DNA sequence was
synthesized (Blue Heron Biotechnology) and subcloned
into BamHI and XhoI sites of a modiﬁed pET32a vector
to create a Thioredoxin(Trx)-HIS6-hTERT(1–200) coding
sequence. The fusion protein of  36kDa was expressed in
BL21(DE3) codon plus E. coli (Stratagene). Cells were
grown at 37 C to an OD (600) of 1.0 and expression
was induced with 0.2mM IPTG at 15 C overnight. Cells
were harvested by centrifugation and frozen at  80 C.
Cell pellets were resuspended in lysis buﬀer (50mM
Tris–Cl pH7.5, 25% v/v glycerol, 500mM NaCl, 0.2%
v/v NP40, 10mM imidazole, 1mM DTT, 0.2mM
TCEP, Roche Complete protease inhibitor cocktail) and
incubated with 0.1mg/ml lysozyme and 0.05mg/ml
DNaseI at 4 C. Cell debris was removed by centrifugation
at 26000g for 30min. Soluble lysate was incubated with
Ni–NTA resin (Qiagen) at 4 C. After washing with 20
column volumes of wash buﬀer (50mM Tris–Cl pH 7.5,
25% v/v glycerol, 1.5M NaCl, 20mM imidazole, 1mM
DTT, 0.2mM TCEP), bound proteins were eluted in
50mM Tris–Cl pH7.5, 25% v/v glycerol, 500mM NaCl,
300mM imidazole (or 50mM imidazole in Supplementary
Figure S1), 1mM DTT and 0.2mM TCEP. Trx-
HIS6-hTERT(1–200) was further puriﬁed by HiTrap SP
cation exchange (GE Healthcare) in a buﬀer of 50mM
Tris–Cl pH 7.5, 25% v/v glycerol, 5mM DTT, 0.2mM
TCEP with a 0.08–1.0M NaCl gradient. The protein
could not be dialyzed to a low-salt buﬀer or concentrated
without undergoing precipitation. The control Trx-HIS6
protein was expressed from pET32a and puriﬁed over
Ni–NTA resin.
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were boiled in SDS–PAGE loading dye and resolved by
denaturing eletrophoresis alongside the RPN5800 (GE
Healthcare) or Benchmark (Invitrogen) molecular weight
markers through 4–20% w/v Tris–Glycine Novex gels
(Invitrogen). Gels were stained with Deep-Purple Total
Protein Stain (GE Healthcare) or Coomassie Brilliant
Blue (Fisher Scientiﬁc), or transferred to a PVDF
membrane (Invitrogen) and subjected to immunoblotting
with anti-Trx primary (Novagen) and sheep anti-mouse
IgG-HRP secondary (GE Healthcare) antibodies and
ECL Plus detection reagents (GE Healthcare). Deep
Purple and ECL Plus ﬂuorescent signals were captured
below saturation using a Typhoon Trio variable mode
imager (GE Healthcare).
Electrophoretic mobility shift assay
Single-stranded DNA bearing the telomeric sequence (TT
AGGG)3 was labeled at the 50-end with
32P. Residual
g-
32P-ATP was removed by centrifugation though a G25
spin column (GE Healthcare). DNA was boiled for 5min
and cooled on ice to minimize secondary structures. Each
20ml binding reaction contained 1nM
32P-(TTAGGG)3,
50mM Tris–Cl pH 7.5, 15% (Figure 1C) or 17.5% v/v
(Figure 4C) glycerol, 450mM NaCl, 5mM DTT and
recombinant Trx-HIS6-hTERT(1–200) protein. For the
heat denaturation control, protein was denatured on a
95–100 C heating block for 5min then cooled on ice
prior to mixture with DNA. Protein–DNA mixtures
were incubated for 30min at room temperature, then
resolved at 15V/cm at 4 C in cold 0.5 TBE through
a pre-cooled gel containing 5% w/v 19:1 acrylamide:
bisacrylamide, 0.5  TBE and 5% v/v glycerol
(Supplementary Figure S1 was conducted under a
voltage gradient; see Supplementary Figure S1 legend
for details). Gels were dried at 80 C for 1h and then
exposed to a phosphorimager screen which was then
scanned on a Typhoon Trio variable mode imager.
Intensity of the DNA shift signal was quantiﬁed using
ImageQuant software (GE Healthcare). For competition
assays, unlabeled DNA of diﬀerent sequence/length was
mixed with
32P-(TTAGGG)3 prior to the addition of
protein. DNA oligonucleotides were obtained from
Integrated DNA Technologies after polyacrylamide gel
electrophoresis (PAGE) puriﬁcation.
Reconstitution of telomerase in reticulocyte lysates
Telomerase activity was reconstituted in rabbit
reticulocyte lysates (RRL) as described (64,65), with mod-
iﬁcations. Human telomerase RNA (hTR) was transcribed
in vitro using the RiboMax kit (Promega) and gel-puriﬁed.
Coupled in vitro transcription–translation reactions
(Promega Corp.) were prepared with 0.01mg/ml
pCR3-FLAG-hTERT-FLAG cDNA and 0.01mg/ml hTR
RNA, and incubated for 90min at 30 C. To generate
hTERT fragments, the following cDNAs were
expressed in separate RRL reactions for 60min: pCR3-
FLAG-hTERT(201–1132)-FLAG; pBiEx3-hTERT
(1–200)-S-HIS8; pET32a-Trx-HIS6-hTERT(1–200).
To combine fragments, 15–20ml of each reaction was
then mixed and incubated for an additional 60min.
Mock reactions did not contain a cDNA template. RRL
mixtures were then diluted to 500ml with cold CHAPS
buﬀer (0.5% w/v CHAPS, 10mM Tris–Cl pH 7.5, 10%
v/v glycerol, 100mM NaCl, 1mM MgCl2 1mM DTT,
Roche EDTA-free complete protease inhibitor cocktail)
and rocked for 1h at 4 C. FLAG-tagged complexes
were immunoprecipitated with anti-FLAG M2 aﬃnity
resin (Sigma) and washed three times with 1ml cold
CHAPS buﬀer. For PCR-based analysis of telomerase
activity, 1ml of the immunoprecipitate was assayed by
the TRAP (described below). The remainder of the pellet
was boiled in SDS–PAGE loading dye and proteins were
resolved through 4–20% w/v Tris–Glycine Novex gels,
transferred to a PVDF membrane (Invitrogen) and sub-
jected to immunoblotting. Primary antibodies employed
were as follows: S protein-HRP (Novagen); rabbit
anti-Trx antibody (Sigma); and mouse anti-FLAG M2
antibody (Sigma). Secondary antibodies employed were
donkey anti-rabbit IgG-HRP and sheep anti-mouse
IgG-HRP (GE Healthcare). Reactive bands were
detected with ECL Plus reagents (GE Healthcare) and
ﬂuorescent signals were captured using a Typhoon Trio
variable mode imager. For direct analysis of primer elon-
gation activity, the entire immunoprecipitate was
analyzed by the standard elongation (SE) assay (described
below).
Telomerase activity assays
Telomerase activity was assessed using the Telomere
Repeat Ampliﬁcation Protocol (TRAP) or SE assay.
TRAP assays were performed using the TRAPeze kit
(Millipore) with modiﬁcations to the manufacturer’s
protocol. Cell lysate or in vitro-reconstituted telomerase
was incubated with the TS primer at 30 C for 30min
prior to heat inactivation at 95 C for 2min. Reactions
were held at 95 C while Taq DNA polymerase (New
England Biolabs) was added. Primer extension products
were ampliﬁed through 25 cycles of 30s at 94 C, 30s at
50 C and 90s at 72 C. Twenty microliters of each 50ml
reaction was combined with DNA loading dye and
resolved through a 10% w/v 19:1 acrylamide:bisa-
crylamide gel in 0.6  TBE at 15–20V/cm. DNA was
stained with SYBR Green I (Sigma) and ﬂuorescent
signals were captured on a Typhoon Trio variable mode
imager.
For SE assays, in vitro-reconstituted telomerase was
incubated with 200pmol PAGE-puriﬁed (TTAGGG)3
(IDT), 40mCi of [a-
32P]-dGTP (Perkin Elmer, 6000Ci/
mmol, 20mCi/ml) and 1  SEA buﬀer (2mM dATP,
2mM dTTP, 1mM MgCl2, 1mM spermidine, 5mM
b-mercaptoethanol, 50mM potassium acetate, 50mM
Tris–acetate pH 8.5) in a 40ml volume for 2h at 30 C.
Samples were treated with RNase A at 37 C for 15min,
followed by Proteinase K at 37 C for 15min. Samples
were phenol:chloroform extracted.
32P-end-labeled
96-mer DNA (150cpm) was added to each reaction as a
loading control. DNA was precipitated overnight at
 20 C by the addition of 1/10 volume sodium acetate
Nucleic Acids Research,2010, Vol.38, No. 6 2021pH 5.2, two volumes cold ethanol and 5mg GenElute
linear polyacrylamide. DNA was pelleted by centri-
fugation and resuspended in 3ml gel loading buﬀer
(100% v/v formamide, 0.6  TBE). Samples were boiled
for 3min and resolved by electrophoresis in 0.6  TBE
through a 10% w/v denaturing polyacrylamide gel
(29:1, acrylamide:bisacrylamide, 7M urea, 0.6  TBE).
The gel was dried at 80 C for 1h, and then exposed to
a phosphorimager screen which was then scanned on
a Typhoon Trio variable mode imager.
Mutagenesis of hTERT(1–200)
The structure-based sequence alignment of the N-terminus
of TERT (51) was used as a guide to select residues in
hTERT(1–200) that may be exposed to the surface of
the protein (refer to Supplementary Figure S4). The
design of PCR primers for site-directed mutagenesis was
aided by The Primer Generator (66). Primers were
obtained from Operon and IDT. The incorporation of
intended mutations into the cDNA (and the absence of
unwanted mutations) was conﬁrmed by DNA sequencing.
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Figure 1. Recombinant hTERT(1–200) interacts with telomeric DNA. (A) Analysis of Trx-HIS6-hTERT(1–200) expressed in E. coli and puriﬁed as
described in ‘Materials and Methods’ section. Proteins were boiled in SDS–PAGE loading dye, resolved through a 4–20% w/v Tris–Glycine Novex
gel and stained with Deep Purple. The mass (ng) of Trx-HIS6-hTERT(1–200) present in lanes 2–5 was determined by comparing the band intensity
of the full length fusion protein (Single asterisk) to the average intensity of bands in the RPN5800 molecular size marker (M, lane 1, 30ng/band).
Molecular mass (kDa) is indicated at the left. Lane 6, Trx-HIS6 (Double asterisk) puriﬁed as described in ‘Materials and Methods’ section.
(B) Proteins prepared as in (A) were transferred to PVDF and immunoblotted with anti-Trx (Novagen) and anti-mouse IgG antibodies. Lane 1
(not shown) contains Benchmark molecular size marker. [Supplementary Figure S3, lanes 7–18 and Figure 3B, lanes 9–10 were probed with a
diﬀerent anti-Trx antibody (Sigma)]. (C) EMSA of telomeric DNA.
32P-(TTAGGG)3 was mixed with the following components as described in
‘Materials and Methods’ section: lane 1, DNA alone; lane 2–5, recombinant Trx-HIS6-hTERT(1–200) [same amounts as in (A) and (B), expressed as
molar ratio to radiolabeled probe]; lane 6, pre-boiled (
b) Trx-HIS6-hTERT(1–200); lane 7, Trx-HIS6 [same amount as in (A) and (B),
expressed as molar ratio to radiolabeled probe]; lanes 9–11, Trx-HIS6-hTERT(1–200) in the presence of unlabeled speciﬁc competitor oligonucleotide
(at the indicated molar ratio to radiolabeled probe). Lanes 5 and 8 are duplicates. Complexes were resolved by native polyacrylamide
gel electrophoresis.
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pcDNA3.1(hyg)-hTERT vectors were linearized with
SspI, treated with calf intestinal phosphatase (New
England Biolabs), and then gel-puriﬁed. Human embry-
onic kidney HA5 cells were transduced with either
wild-type or mutant hTERT DNA using FuGENE6
transfection reagent (Roche). Cells were grown in
alpha-Minimal Essential Medium (a-MEM) containing
10% v/v fetal bovine serum and 2mM L-glutamine, and
then selected with 200mg/ml (Supplementary Figure S5) or
100mg/ml hygromycin (Figure 5). Cells undergoing mock
transfection (with no DNA) did not survive selection.
After 4–5 weeks of selection, colonies were treated with
TrypLE Express (Invitrogen) and pooled. Polyclonal pop-
ulations were passaged in media containing hygromycin
by plating 2 10
5 cells in a 10cm plate at regular intervals.
The number of cumulative population doublings at each
passage was determined by the formula as described (67).
The experiment was performed with late-passage cells
approaching crisis (Supplementary Figure S5), and also
with cells at an earlier passage (Figure 5). Apoptosis was
assessed using the TiterTACS assay (R&D Systems) and
by visual inspection of cellular morphology by
microscopy.
Protein extraction
Cells were washed with ice-cold PBS and dislodged from
tissue culture plates using a cell scraper. Cells were
resuspended and lysed in 4–5 volumes of ice-cold
CHAPS buﬀer (0.5% w/v CHAPS, 10mM Tris–Cl
pH 7.5, 10% v/v glycerol, 1mM MgCl2,5 m M
b-mercaptoethanol, Roche EDTA-free Complete
protease inhibitor and 400U Roche RNase Inhibitor)
for 30min on ice. Insoluble material was pelleted by
centrifugation at 13000r.p.m. for 30min. The protein
concentration of the cleared whole cell extract was deter-
mined by the Bradford Assay (Bio-Rad).
Analysis of mRNA by RT–PCR
Total RNA was isolated from cells using TRIzol reagent
(Invitrogen), and then treated with DNase I (Roche).
cDNA was generated from RNA using Superscript II
reverse transcriptase (Invitrogen) and random hexamer
primers (Invitrogen). Residual RNA was removed from
cDNA products using RNase H (Invitrogen). cDNAs
were ampliﬁed by PCR using Taq DNA polymerase
(New England Biolabs) under the following conditions:
94 C for 5min, followed by 32 cycles of 94 C for 45s,
57 C for 45s and 72 C for 1min, followed by a ﬁnal exten-
sion of 72 C for 4min. The following gene-speciﬁc primers
were used: GAPDH,5 0-CGGAGTCAACGGATTTGGT
CGTAT-30 and 50-TGCTAAGCAGTTGGTGGTGCAG
GA-30; hTERT,5 0-AAGTTCCTGCACTGGCTGATGA
G-30 and 50-TCGTAGTTGAGCACGCTGAACAG-30;
hygromycin resistance (HYG-R), 50-CGCAAGGAATCG
GTCAATAC-30 and 50-ACATTGTTGGAGCCGAAA
TC-30. DNA was resolved through a 0.8% w/v agarose
gel, stained with ethidium bromide, and imaged on a
Typhoon Trio variable mode imager.
Telomere length analysis
Genomic DNA was isolated from cells using the DNeasy
kit (Qiagen) and digested with RsaI and HinfI. Restriction
fragments were resolved through a 0.5% w/v agarose gel
at 45V (2V/cm) for 24h. DNA was denatured in buﬀer
containing 0.5M NaOH, 1.5mM NaCl for 30min, and
neutralized in buﬀer containing 1.5M NaCl, 0.5mM
Tris–Cl pH 7.5 for 30min. DNA was transferred
to Hybond N+ membrane in 20  SSC. Following
transfer, DNA was UV-crosslinked to the membrane,
which was then rinsed in 2 SSC. Telomeric DNA was
hybridized to a
32P5 0-end-labeled (CCCTAA)3 probe in
Church buﬀer (0.5M NaPO4 pH 7.2, 1% w/v BSA, 7%
w/v SDS, 1mM EDTA), then washed with 1  SSC, 0.1%
w/v SDS. The membrane was exposed to a phosphori-
mager screen which was then scanned using a Typhoon
Trio variable mode imager. The weighted mean of
telomere length in each lane was calculated according
the following formula, as previously described (68):
 (ODi)/ (ODi/Li), where ODi is the signal intensity and
Li is the length in nucleotides of DNA at position i
as determined by comparison to the molecular mass
standards.
RESULTS
Production of recombinant hTERT(1–200) in a bacterial
expression system
The N-terminus of T. thermophila TERT contains a
DNA-binding domain (51–53). Mutations in this region
impair telomerase activity, as do mutations in the equiva-
lent region of hTERT (55,58–63). Thus, this region has
been dubbed the telomerase essential N-terminal (TEN)
domain (51). Although the N-terminus of TERT
contains a region of homology (GQ), the sequence conser-
vation between human and T. thermophila TERTs in this
region is especially low. Unpuriﬁed hTERT(aa 1–300)
and hTERT(1–350) generated in reticulocyte lysates
can be captured onto biotinylated telomeric DNA in
a neutravidin pull-down assay [(55), D.C.F. Sealey and
L.A. Harrington, unpublished results]. To clarify this
apparent hTERT–DNA interaction, we developed a
strategy to produce recombinant hTERT in bacteria.
We expressed Trx-HIS6-hTERT(1–200) in E. coli and,
despite a low expression level and limited solubility (<5%
of expressed protein was recovered in the soluble fraction
of the cell lysate), we puriﬁed the protein over two chro-
matographic steps to a modest degree of homogeneity (see
‘Materials and Methods’ section). The fusion protein was
detected at the expected size of 36kDa (Figure 1A). The
presence of Trx fused at the N-terminus was conﬁrmed by
western blotting (Figure 1B) and the identity of TERT was
conﬁrmed by tandem mass spectrometry (MS) (T. Goh
and T. LeBihan, data not shown). Minor bands at
higher molecular weights were identiﬁed as the bacterial
chaperones DNaK and DNaJ and the translation elonga-
tion factor Tu (T. Goh and D.C.F. Sealey data not
shown). The majority of peptides derived from the lower
molecular weight bands, some of which were reactive to
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Trx-HIS6-hTERT(1–200) based on MS analysis (Figure
1B and data not shown). The purity of full length
Trx-HIS6-hTERT(1–200) in a typical puriﬁcation was
determined to be 75% based on Coomassie staining
(data not shown). Based on Deep Purple staining (which
is more sensitive than Coomassie), purity was determined
to range from 20% (Figure 1A) to 40% (Figure 4A).
hTERT(1–200) interacts with telomeric DNA in vitro
To determine whether hTERT(1–200) interacts with
DNA, we performed EMSAs. Recombinant Trx-HIS6-
hTERT(1–200) was mixed with radiolabeled
single-stranded DNA oligonucleotides containing three
full telomeric repeats and subjected to native
polyacrylamide gel electrophoresis. A slower mobility
complex contained labeled DNA, and this complex
increased in intensity upon addition of increasing
amounts of protein (Figure 1C). The DNA shift reached
a maximum when the binding mixture contained 450mM
NaCl, and persisted in 1M NaCl (data not shown). Heat
denaturation of the protein preparation inactivated the
apparent DNA-binding activity (Figure 1C, lane 6). The
gel shift observed with radiolabeled DNA was, as
expected, competed by an excess molar ratio of unlabeled,
speciﬁc oligonucleotide (Figure 1C, lanes 9–11). An
extract prepared from cells expressing Trx-HIS6 and
puriﬁed over Ni–NTA resin (in the same manner as
Trx-HIS6-hTERT) did not interact with telomeric DNA
(Figure 1C, lane 7). Furthermore, the electrophoretic
mobility of telomeric DNA in complex with
Trx-HIS6-hTERT [or another hTERT(1–200)-S-HIS
fusion protein] was altered upon the addition of
anti-HIS antibody but not other antibodies. Speciﬁcally,
a slower mobility complex disappeared upon incubation
with increasing concentrations of anti-HIS antibody, con-
comitant with the enrichment or appearance of faster
mobility complexes (Supplementary Figure S1).
Antibodies speciﬁc to their cognate protein often elicit a
‘supershift’ (i.e. retardation of mobility) upon binding to
the DNA:protein complex. Although not as common,
antibody recognition can perturb the intact nucleoprotein
complex leading to the disappearance of complexes, or
appearance of faster mobility complexes, owing to an
alteration of relative DNA:protein stoichiometry
(69–71). These data show that hTEN was present in the
telomeric DNA complex, and argue for a speciﬁc interac-
tion between the N-terminus of hTERT and telomeric
DNA.
hTERT(1–200) interacts preferentially with telomeric
DNA of a particular register and suﬃcient length
To determine the DNA-binding speciﬁcity of the hTEN
complex, we tested the ability of unlabeled competitor
DNA oligonucleotides of diﬀerent length and/or telomeric
register to compete with labeled (TTAGGG)3 for binding
to Trx-HIS6-hTERT(1–200), and expressed the rela-
tive apparent binding aﬃnities as the amount of
oligonucleotide required to reduce the signal intensity of
the mobility shift by 50% (Figure 2, Supplementary
Figure S2 and data not shown). Single-stranded
oligonucleotides 18 nucleotides (nt) in length did not
require a speciﬁc 50-o r3 0-end in the telomeric register to
facilitate binding (Figure 2A, compare oligonucleotides I,
II). Oligonucleotides ending in GGG required at least
13nt of telomeric sequence to bind comparably to the
18nt (TTAGGG)3 probe (I, III, IV, V). For
oligonucleotides 13nt in length, a speciﬁc telomeric
register was preferred: in decreasing order of apparent
aﬃnity, oligonucleotides that terminated in GGG, GG
and G (IV, VI, IX). Reducing the length to 12nt in any
register reduced the apparent binding aﬃnity (compare IV
and V; VI and VII; IX and X). Oligonucleotides 12nt in
length were recognized when containing, in decreasing
order of apparent aﬃnity, terminal GG, GGG, G and
no G (VII, V, X, XIII). Reducing oligonucleotide length
to 11nt reduced the apparent aﬃnity for DNA ending in
GG (VII and VIII); when ending in G, a further decrease
in apparent aﬃnity was observed only upon decreasing the
length to 10nt (X, XI, XII). Surprisingly, for
oligonucleotides ending in TTA, 11nt (but not 10nt)
bound with a greater apparent aﬃnity than did 12nt
(XIII, XIV, XV). From this dataset, we conclude that
single-stranded telomeric DNA 13nt in length and
terminating in GGG or GG was a preferred substrate
for hTEN binding (IV, VI), whereas oligonucleotides of
this length with diﬀerent telomeric registers, or shorter
oligonucleotides, did not bind with a comparable
apparent aﬃnity.
To determine the sequence speciﬁcity of the DNA inter-
action, we performed another set of competition experi-
ments with oligonucleotides containing non-telomeric
substitutions (Figure 2B). Telomeric DNA 18nt in
length in which the middle G at position 11 was
replaced with C had a 7-fold lower apparent aﬃnity for
hTEN (compare I and I.C11). For telomeric DNA 13nt in
length and ending in a GG register (VI), replacing G with
C signiﬁcantly reduced apparent aﬃnity at some positions
(VI.C1, C6, C7, C12, C13) but not others (VI.C2, C8).
Interestingly, replacing the central GGG with TTA did
not reduce apparent aﬃnity (VI.TA6), whereas replacing
the GG with TA at the 50- and 30-ends did reduce apparent
aﬃnity (VI.TA1.12). Combining these central, 50 and 30
GG-to-TA replacements reduced apparent aﬃnity
(VI.TA1.6.12), suggesting that GG residues form critical
contacts with hTEN and that the central GGG, while not
required, does stabilize the interaction in the absence of
other G contacts. Inverting the GGG and TA positions
across the 13nt also reduced relative binding aﬃnity
(VI.INVERT), again suggesting that GG ‘bookends’ facil-
itate the hTEN:DNA interaction, and that the relative
positions of internal G residues are also important.
Taken together, these data indicate that the interaction
of hTEN with oligonucleotides 13nt in length depends
on G-rich character at certain positions—a demonstration
of telomere sequence speciﬁcity (Figure 2B, lower), and in
keeping with previous observations on the preferred
substrate composition for elongation by telomerase (see
‘Discussion’ section).
2024 Nucleic Acids Research, 2010,Vol.38, No. 6hTERT(1–200) can restore activity to the inactive
hTERT(201–1132) fragment in trans
N-terminal fragments of hTERT can restore enzymatic
function, in trans, to inactive fragments of the remainder
of hTERT in combination with hTR (59,62). Since
hTERT(201–1132) possesses an activity defect (58), we
reasoned that providing the hTEN DNA-binding
domain in trans may restore its activity. We reconstituted
telomerase activity in RRLs by expressing FLAG-hTERT
cDNA in the presence of hTR, and assayed anti-FLAG
immunoprecipitates for telomerase activity (see ‘Materials
and Methods’ section). Whereas wild-type hTERT dis-
played a characteristic ability to generate long extension
products (Supplementary Figure S3, lane 1; and Figure 3A
and B, lane 1), removal of the ﬁrst 200 amino acids nearly
abolished this activity (Supplementary Figure S3, lane 2;
and Figure 3A and B, lane 2), as demonstrated previously
(58,59). However, when mixed with hTERT(1–200) (con-
taining Trx or an S-tag at the N- or C-terminus, respec-
tively) after separate translation in RRL, the two
fragments interacted with one another and catalytic
activity was restored (Supplementary Figure S3, lanes 3
and 7; Figure 3A, lane 3; Figure 3B, lanes 3 and 9). (Note:
hTR was not required for the interaction of hTERT
N- and C-termini; Supplementary Figure S3, lanes 5,
13 and 14.) Therefore, hTERT(1–200) is essential for
A
B
Sequence - L  (n) Name
TTAGGGTTAGGGTTAGGG - 18 (1) I
GGGTTAGGGTTAGGGTTA    - 18 (1) II
GGGTTAGGGTTAGGG - 15 (2) III
GTTAGGGTTAGGG - 13 (2) IV
TTAGGGTTAGGG - 12 (2) V
GGTTAGGGTTAGG  - 13 (3) VI
GTTAGGGTTAGG  - 12 (3) VII
TTAGGGTTAGG  - 11 (1) VIII
GGGTTAGGGTTAG   - 13 (1) IX
GGTTAGGGTTAG   - 12 (3) X
GTTAGGGTTAG   - 11 (3) XI
TTAGGGTTAG   - 10 (1) XII
GGGTTAGGGTTA    - 12 (1) XIII
GGTTAGGGTTA    - 11 (3) XIV
GTTAGGGTTA    - 10 (1) XV
TTAGGGTTAGGGTTAGGG - 18 (4) I
TTAGGGTTAGCGTTAGGG - 18 (4) I.C11
GGTTAGGGTTAGG  - 13 (4) VI
CGTTAGGGTTAGG  - 13 (4) VI.C1
GCTTAGGGTTAGG  - 13 (4) VI.C2
GGTTACGGTTAGG  - 13 (5) VI.C6
GGTTAGCGTTAGG  - 13 (6) VI.C7
GGTTAGGCTTAGG  - 13 (5) VI.C8
GGTTAGGGTTACG  - 13 (5) VI.C12
   GGTTAGGGTTAGC  - 13 (5) VI.C13
 GGTTATTATTAGG  - 13 (3) VI.TA6
TATTATTATTATA  - 13 (3) VI.TA1.6.12
TAGGGTTAGGGTA  - 13 (3) VI.INVERT
TATTAGGGTTATA  - 13 (5) VI.TA1.12
01 0 0
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**
**
**
**
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*
GGTTAGGGTTAGG
-+   --+   --
--   +++   --
C
TA
Effect of nucleotide substitution on 
affinity for hTERT(1-200):
(-) decrease  (+) no decrease
Figure 2. DNA sequence and length preferences for binding of hTERT(1–200). (A and B)
32P-(TTAGGG)3 was incubated with a molar excess of
unlabeled competitor prior to addition of Trx-HIS6-hTERT(1–200). Complexes were resolved by EMSA. (An example of the raw data is shown in
Supplementary Figure S2.) X-axis indicates the molar ratio of unlabeled competitor oligonucleotide relative to
32P-(TTAGGG)3 required to reduce
the Trx-HIS6-hTERT(1–200)-dependent gel shift signal by 50% (relative IC50). Y-axis indicates the sequence, length (L), number of replicates (n) and
name of oligonucleotides tested. To conﬁrm the reproducibility of results, (A) and (B) were performed with diﬀerent elution fractions from the same
puriﬁcation. (A) Relative apparent binding aﬃnities of DNA oligonucleotides with diﬀerent length and telomeric register. A one-tailed t-test for
samples with equal variance was used to conclude signiﬁcance (*P<0.05; compare VI and VII). (B) Relative apparent binding aﬃnities of telomeric
DNA oligonucleotides with non-telomeric substitutions. A two-tailed t-test for samples with unequal variance was used to identify signiﬁcant
decreases in aﬃnity relative to the unmodiﬁed telomeric oligonucleotide of identical length (*P<0.05, **P<0.025, ***P<0.006). The bottom
schematic indicates positions at which nucleotide substitutions decrease ( ) or do not decrease (+) the interaction with hTERT(1–200).
Nucleic Acids Research,2010, Vol.38, No. 6 2025telomerase activity in vitro, and can function as a separa-
ble domain to restore activity to an inactive fragment of
hTERT. While recombinant, puriﬁed Trx-HIS-hTERT(1–
200) interacted with hTERT(201–1132), this puriﬁed prep-
aration was unable to regenerate in activity in combination
withhTERT(201–1132)(SupplementaryFigureS3,lanes8,
14 and 17; Figure 3B, lane 10) (see ‘Discussion’ section).
Identiﬁcation of amino acids in hTERT(1–200) that are
critical for telomerase activity in vitro
Although the ﬁrst 200 amino acids of human and
T. thermophila TERTs share <15% identity and 25% sim-
ilarity, the N-terminus of hTERT may still adopt a similar
three-dimensional fold. Guided by the sequence alignment
of the N-terminus of hTERT to the T. thermophila TERT
TEN domain structure (51), we generated point mutations
in acidic, basic and polar residues in hTEN that are poten-
tially exposed to the surface, and assayed mutants in the
context of hTEN for the ability to restore function to
hTERT(201–1132) (refer to Supplementary Figure S4).
Many of the mutations, including T116A/T117A/S118A,
exhibited no discernible eﬀect on telomerase activity or the
ability to interact with hTERT(201–1132)+hTR
(Figure 3A and B, lanes 5 and 7, and data not shown;
summarized in Table 1). In contrast, mutation of Q169A
in hTERT(1–200)-S-HIS8 or Trx-HIS6-hTERT(1–200)
impaired telomerase function as assayed by TRAP
(Figure 3A, lane 8 and data not shown; Table 1).
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Figure 3. hTERT(1–200) rescues the activity defect of hTERT(201–1132) in a Y18- and Q169-dependent manner. FLAG-tagged hTERT(201–1132)
was mixed with mock RRL (lane 2), wild-type (lane 3) or mutant hTERT(1–200)-S-HIS8 containing substitutions at the indicated positions
(lanes 4–8) and immunoprecipitated onto anti-FLAG resin (IP). FLAG-hTERT(1–1132) was mixed with mock RRL as a positive control (lane
1). (A) Telomerase activity in the IPs was assessed by TRAP. Irrelevant lanes between 8 and 9 were removed. Buﬀer alone (CHAPS) was assayed as a
negative control (lane 9). Immunoprecipitates (IP) were analyzed by western blotting using S protein-HRP (WB1), followed by anti-FLAG M2 and
anti-mouse IgG antibodies (WB2). Fifteen percent of input protein (In) was analyzed on a separate blot with S protein-HRP. (B) Telomerase activity
in the IPs was analyzed using a radioactive, linear standard elongation (SE) telomerase assay. Lane 9, 10, Trx-HIS-hTERT(1–200) produced in RRL
or bacteria, respectively. Lane 11, position of the (TTAGGG)3 DNA oligonucleotide upon 50-end-labeling with
32P (bottom arrowhead). Lane 12,
96nt loading control (top arrowhead) that was added to each reaction prior to the recovery of extension products. Bottom panel: 15% of input
protein was analyzed by western blotting using S protein-HRP (lanes 3–8). Fifteen and 60% of input protein were analyzed in lanes 9 and 10,
respectively, using anti-Trx (Sigma) and anti-rabbit IgG-HRP antibodies.
2026 Nucleic Acids Research, 2010,Vol.38, No. 6Also, Q169A rendered telomerase unable to catalyze
nucleotide addition in the SE assay—an unequivocal indi-
cation that Q169 is required for catalytic activity
(Figure 3B, lane 8 and data not shown; Table 1) similar
to the requirement for Q168 in T. thermophila TERT (51).
The H17A/Y18A/R19A mutant displayed a similar inabil-
ity to elongate telomeric DNA, although the defect by
TRAP was not as pronounced (Figure 3A and B, lane 4;
Table 1). The defect of the triple mutant was attributed to
a single amino acid change at Y18, but not H17 or R19
(Figure 3A and B, lanes 5–7). None of the mutations
described above disrupted the interaction with
hTERT(201–1132)+hTR (Figure 3A).
Y18 or Q169 are dispensable for the interaction of
hTERT(1–200) with DNA
To further study the eﬀect of hTEN mutation on the bio-
chemical activities of telomerase, we produced hTEN
mutants in bacteria alongside wild-type hTEN in the
same manner as described above. Puriﬁcations of
Trx-HIS6-hTERT(1–200) wild-type, Y18A, T116A/
T117A/S118A and Q169A contained a prominent band
at the expected size that was recognized by anti-Trx
antibody (Figure 4A and B). Lower molecular weight
fragments of the fusion protein co-puriﬁed with the
intact protein, as in our puriﬁcation of wild-type hTEN
(see also Figure 1B). Only Q169A contained a noticeable
truncation product at 31kDa that was recognized
by anti-Trx antibody and was present in equal abun-
dance to the full-length 36kDa fusion protein
(Figure 4A and B).
To determine whether residues in hTEN that are
required for activity are required for DNA binding, we
performed EMSAs with hTEN mutants. As before,
Trx-HIS6-hTERT(1–200) shifted the single-stranded
telomeric DNA oligonucleotide in a native gel in a
concentration-dependent manner (Figure 4C, lanes 2–4).
The T116A/T117A/S118A mutant also bound telomeric
DNA (Figure 4C, lanes 8–10), which is consistent with
the predicted position of these residues on the surface of
the domain opposite the putative DNA-binding groove,
and an apparent lack of involvement in the catalytic
Table 1. Summary of hTERT mutant phenotypes
Allele Telomerase activity
a DNA binding
b Cell lifespan extension
c Predicted surface
d
TRAP SE
Normal activity, binds DNA, extends cellular lifespan
WT + (17, 4
e) + (7, 1
e) + + (2)
Normal activity, binds DNA, does not extend cellular lifespan
T116A/T117A/S118A + (3) + (1) +   (2) A/B
Defective activity, binds DNA, does not extend cellular lifespan
H17A/Y18A/R19A   (8)   (4)   (3) A/B.G
Y18A   (3)   (4) + ? (1) A/B.G
Q169A   (10, 2
e)   (3) +   (3) A.G
Normal activity (not tested: DNA binding, cellular lifespan extension)
R15A/S16A + (3) + (1) A/B.G
H17A + (5) + (4) ... ... ... ... A/B
R19A + (5) + (4) A/B.G
R29A/R30A + (3) + (2) B
Q34A/R37A + (5) + (1) ... ... ... ... B
R48A + (3) + (1) A/B
Q53A + (3) + (1) A/B
S70A/R72A/Q73A + (3) + (1) ... ... ... ... B
D105A + (3) + (1) B
E113A + (3) + (1) A
S121A/Y122A + (3) + (1) ... ... ... ... A
D129A + (3) + (1) A.G
S134A + (3) + (1) A
R155A + (3) + (1) ... ... ... ... B
T182A/Q183A/R185A + (5) + (1) A/B.G
H189A/S191A + (3) + (2) A/B.G
‘+’ no defect or ‘ ’ defect. Phenotype representative of (n) experimental replicates.
aTelomerase was reconstituted by mixing RRL-expressed hTERT(1–200)-S-HIS8 with FLAG-hTERT(201–1132)-FLAG in the presence of hTR.
bTrx-HIS6-hTERT(1–200), puriﬁed from bacteria, was mixed with (TTAGGG)3 and complexes were analyzed by electrophoretic mobility shift assay
(EMSA).
cHA5 cells stably expressing hTERT(1–1132) were passaged under selection. (?) indicates that expression of the Y18A mutant was lost during the
experiment, precluding a conclusion regarding loss of function.
dSee Supplementary Figure S4. Predicted surface position based on alignment of the hTERT sequence to the structure of the T.thermophila TERT
TEN domain (51). Side ‘A’ includes the putative DNA-binding groove. Side ‘B’ faces opposite Side ‘A.’ A/B represents an edge between both sides.
G indicates a location in/near the putative DNA-binding groove. Refer to ‘Materials and Methods’ section for additional details.
eTelomerase was reconstituted by mixing RRL-expressed Trx-HIS6-hTERT(1–200) with FLAG-hTERT(201–1132)-FLAG in the presence of hTR.
Anti-FLAG immunoprecipitates were assayed for telomerase activity by TRAP or SE protocols.
Nucleic Acids Research,2010, Vol.38, No. 6 2027reaction cycle (Table 1, Supplementary Figure S4).
Interestingly, mutation of Y18 or Q169, each of which
impaired telomerase activity, did not aﬀect the ability of
hTEN to bind telomeric DNA (Figure 4C, lanes 5–7,
11–13). One could infer that these resides do not contact
DNA, or that these residues may contact DNA (based on
their predicted positions in/near the putative
DNA-binding groove) but that neither Y18 nor Q169 is
the sole determinant of a DNA interaction—at least not to
an extent that can be resolved by the EMSA assay. The
ability of hTEN(Q169A) to bind telomeric DNA in an
EMSA diﬀers from the reduced primer crosslinking
ability of T. thermophila TERT(Q168A) (51) (see
‘Discussion’ section).
Residues in hTERT(1–200) are required for
telomerase-mediated extension of cellular lifespan
To determine whether Y18 and Q169, as determinants of
telomerase activity in vitro, are also required for
telomerase function in cells, we performed a cellular
immortalization experiment. We created polyclonal HA5
cell lines [HA5 is a mortal, SV40-transformed human
embryonic kidney cell line that bypasses senescence and
205
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Figure 4. Selected mutations in hTERT(1–200) do not abrogate DNA-binding activity. (A) Analysis of Trx-HIS6-hTERT(1–200) (wild-type or
mutant, as indicated) expressed in E. coli and puriﬁed as described in ‘Materials and Methods’ section. Proteins were boiled in SDS–PAGE
loading dye, resolved through a 4–20% w/v Tris–Glycine Novex gel and stained with Deep Purple. The mass (ng) of Trx-HIS6-hTERT(1–200)
present in lanes 2–13 was determined by comparing the band intensity of the full-length fusion protein (*) to the average intensity of bands in the
RPN5800 molecular size marker (M, lane 1, 30ng/band). Molecular mass indicated at left (kDa). (B) Proteins prepared as in (A) were transferred to
PVDF and immunoblotted with anti-Trx (Novagen) and anti-mouse IgG-HRP antibodies. (C) Electrophoretic mobility shift assay of telomeric
DNA.
32P-(TTAGGG)3 was mixed with the following components as described in ‘Materials and Methods’ section: lane 1, DNA alone; lanes 2–13,
increasing amounts of wild-type or mutant Trx-HIS-hTERT(1–200) [same amounts as in (A) and (B); expressed as molar ratio to radiolabeled
probe]. Complexes were resolved by native polyacrylamide gel electrophoresis.
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Figure 5. Selected mutations in the N-terminus of hTERT interfere with the ability of telomerase to extend the replicative lifespan of primary human
(HA5) cells. (A) Polyclonal cell lines containing wild-type or mutant hTERT cDNA (or pcDNA3.1 as a negative control) were derived from HA5
cells (at earlier passage than cells used in Supplementary Figure S5). Cells were passaged under selection with hygromycin. Y-axis contains a break
spanning population doublings (PD) 35–55 in order to display the uninterrupted growth of cells expressing wild-type hTERT. (B) Lysates of
polyclonal cell lines containing wild-type or mutant hTERT cDNA were prepared in CHAPS buﬀer at Day 35 and assayed for telomerase
activity by TRAP. CHAPS buﬀer was assayed as a negative control (lane 8). HeLa cell lysate was assayed as a positive control (lane 9). IC indicates
TRAP internal control product. Lanes containing irrelevant samples were omitted. (C) Analysis of hTERT mRNA expression level at early and late
passage by RT–PCR. Hygromycin resistance (HYG-R, upper), hTERT (middle) and GAPDH cDNAs were ampliﬁed using gene-speciﬁc primers
(refer to ‘Materials and Methods’ section). Lanes containing irrelevant samples were omitted. (D) Analysis of the terminal telomere restriction
fragments (TRF) at the indicated population doubling (PD) of polyclonal HA5 cell lines receiving wild-type or mutant hTERT. Genomic DNA was
isolated, digested with RsaI and HinfI, and subjected to Southern blotting using a (CCCTAA)3 probe (refer to ‘Materials and Methods’ section).
Molecular size (kbp) is shown at left according to the migration of 1kbp+DNA ladder (not shown). Left, middle and right panels were analyzed
separately and aligned according to duplicate samples contained on individual blots (not shown). The weighted mean of telomere length (kbp) is
indicated at the bottom of each lane. The presence of an interstitial, cross-hybridizing band at 3kbp can be used to estimate the relative DNA
loading of each lane.encounters crisis—characterized by telomere instability
and apoptosis—and does not undergo spontaneous
immortalization (72)] stably expressing wild-type or
mutant hTERT, and monitored population doubling
levels at regular intervals. Cells that received wild-type
hTERT cDNA continued to divide through the duration
of the experiment, whereas cells receiving empty vector
(pcDNA3.1) or hTERT(D868A/D869A) (mutations that
inactivate reverse transcriptase activity) succumbed to
apoptosis within  10 population doublings (Supple-
mentary Figure S5, data not shown), which is consistent
with previous observations (17,73). Cells receiving
hTERT(H17A/Y18A/R19A) (n=2), Q169A (n=2), or
T116A/T117A/S118A mutants (n=1) were also unable
to divide beyond 10 population doublings.
To conﬁrm these results, we derived a second set of
stable lines from HA5 cells at an earlier passage. As
before, cells receiving wild-type hTERT survived
through the duration of the experiment. In contrast,
cells receiving mutant hTERT cDNA failed to survive
beyond 15–20 population doublings (Figure 5A). This
delay in reaching crisis relative to HA5 cells transduced
at a later passage (Supplementary Figure S5) is in keeping
with the diﬀerent initial telomere lengths of these two pop-
ulations (10). We assayed telomerase activity in lysates
prepared from cells at day 35 in the experiment
(Figure 5B). Lysates from cells containing H17A/Y18A/
R19A, Y18A, Q169A, or D868A/D869A mutants did not
display telomerase activity, which is consistent with the
reduced activity of these mutants in reticulocyte lysates
(Figures 5B, 3A and B, Table 1) (17,65). Although
T116A/T117A/S118A reconstituted telomerase activity
in vitro, cells containing this mutant did not display elon-
gation activity (Figure 5B, Table 1).
Analysis of mRNA transcript levels conﬁrmed expres-
sion of the vector-encoded hygromycin resistance gene at
early and late time points in the experiment (Figure 5C).
Expression of hTERT(WT), H17A/Y18A/R19A, T116A/
T117A/S118A and D868A/D869A alleles was maintained
at later population doublings. Expression of Y18A was
not maintained (Figure 5C, lanes 7 and 8); thus, we
could not formally conclude that this mutant cannot
immortalize cells. Notably, Y18A phenocopied H17A/
Y18A/R19A in vitro and H17A/Y18A/R19A-transduced
cells did not survive (Table 1). Q169A was expressed at
a lower level than wild-type hTERT in the second exper-
iment, but at a comparable level in the ﬁrst experiment
(Figure 5C, lanes 11 and 12 versus 3 and 4; Supplementary
Figure S6, lanes 3 and 4, and 5 and 6 versus lane 2).
Regardless of the level of expression, Q169A did not
reconstitute activity in lysates (Supplementary Figure S6,
lanes 3–5). Therefore, we conclude that hTERT-Q169A
cannot immortalize cells (Table 1). Although none of the
aforementioned mutants immortalized cells, we did
identify mutants that enabled the reconstitution of
telomerase activity in lysates and the extension of
cellular lifespan (D.C.F. Sealey and M. Taboski
unpublished results).
To determine whether mutations in hTEN interfere with
the ability of telomerase to maintain telomeres, we
analyzed telomere length changes in HA5 stable cell
lines by terminal restriction fragment (TRF) analysis.
Average telomere lengths in cells expressing wild-type
hTERT were maintained up to population doubling 16
(Figure 5D, lane 4), whereas telomeres in cells expressing
H17A/Y18A/R19A, T116A/T117A/S118A, Q169A or
D868A/D869A mutants became shorter as the popula-
tions reached crises (Figure 5A and D). The average
telomere length of cells expressing wild-type hTERT
became shorter beyond population doubling 16
(Figure 5D, lanes 5–7), but the population did not encoun-
ter crisis (Figure 5A). This result is consistent with the
ﬁndings of other studies that the maintenance of
minimal telomere DNA by hTERT is suﬃcient for
lifespan extension (74,75). Analysis of telomere length
changes in cells from the ﬁrst immortalization experiment
(Supplementary Figure S5) revealed similar results (data
not shown). Therefore, the mutations in hTEN that we
have described render telomerase unable to maintain
telomeres and extend cellular lifespan.
DISCUSSION
In this study, we described the ability of the N-terminus
of hTERT (hTEN, a.a. 1–200) to interact with
telomeric DNA, and complement the activity defect of
hTERT(201–1132)+hTR as a separable domain.
Mutational analysis identiﬁed that Y18 and Q169
residues were required for primer extension activity
in vitro. These residues, as well as T116/T117/S118, were
required for telomere length maintenance and
telomerase-mediated extension of cellular lifespan, but
not for the interactions of hTEN with DNA or
hTERT(201–1132)+hTR.
Many previous studies have used telomerase activity as
a read-out for investigating telomerase-primer interac-
tions, in part due to the diﬃculty of producing suﬃcient
quantities of puriﬁed hTERT to measure DNA binding
directly. By EMSA (Figures 1C and 2), we demonstrated
that the interaction between puriﬁed Trx-HIS6-hTERT
(1–200) and telomeric DNA was independent of hTR,
other domains of hTERT and telomerase activity. The
interaction was reproducible across independent puriﬁca-
tions of protein and many experimental replicates. The
recombinant protein also interacted with hTERT
(201–1132) (Supplementary Figure S3). Despite these
interactions, Trx-HIS6-hTERT(1–200) produced in
bacteria did not regenerate telomerase activity in combi-
nation with RRL-hTERT(201–1132)+hTR (Figure 3,
Supplementary Figure S3), suggesting that E. coli may
not provide the folding pathways, modiﬁcation activities,
or binding partners required for telomerase activity that a
eukaryotic system can provide (65,76–78). This inability to
support catalysis was not due to interference of the
N-terminal Trx-HIS6 tag, since Trx-HIS6-hTERT
(1–200) produced in RRL conferred a comparable level
of telomerase activity as did RRL-produced hTERT(1–
200)-S-HIS8 (Supplementary Figure S3). Attempts to
activate bacterial Trx-HIS6-hTERT(1–200) with RRL
components were unsuccessful (data not shown).
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most successful of several strategies we attempted.
Codon optimization for expression in E. coli improved
yield signiﬁcantly (data not shown), but we were unable
to obtain enough concentrated Trx-HIS6-hTERT(1–200)
to conduct crystallization trials or determine an aﬃnity
constant for DNA. In EMSA experiments, we were
limited by the total amount and concentration of
puriﬁed protein, and thus did not observe a quantitative
shift of the probe that would be necessary to estimate
binding aﬃnities. Nevertheless, we determined the
relative aﬃnity of hTEN for DNA oligonucleotides of dif-
ferent sequence and length (Figure 2). DNA 13-nt-long
ending in either GGG or GG and containing G residues
at speciﬁc positions was a preferred substrate for
Trx-HIS6-hTERT(1–200) binding, which establishes that
hTEN exhibits length and sequence preference for binding
telomeric DNA (Figure 2). The sequence speciﬁcity of the
interaction, changes in the mobility shift upon incubation
with anti-HIS antibody, and the lack of DNA-binding
activity in E. coli lysates expressing Trx-HIS6
alone argue for a speciﬁc interaction between puriﬁed
hTEN and telomeric DNA. The preference of hTEN for
telomeric DNA parallels that of endogenous telomerase—
a substrate preference that has been, in some instances,
attributed to the putative anchor site. For example,
oligonucleotides longer than 10–12nt are necessary for
high aﬃnity binding and processive elongation, and sub-
stitution of 50 residues (particularly guanines) for
non-telomeric residues impairs primer utilization and
crosslinking (44–49,79).
Despite the limited sequence similarity among the
N-termini of ciliate, yeast and human TERTs (40), the
DNA-binding function of the domain appears to be
conserved. The recombinant N-termini of Est2 and
TtTERT have been shown to interact with DNA in ﬁlter
binding and crosslinking assays, respectively (40,51,53).
Telomerase puriﬁed from yeast cells forms crosslinks to
DNA via the N-terminus of Est2 (measured in an
RNA-dependent assay) (54). Consistently, crosslinking
of TtTERT (puriﬁed from RRL) to DNA is reduced
upon removal of the N-terminus (51,53). Also, the
extent of crosslinking of TtTERT to DNA is reduced
upon mutation of residues in the N-terminus of
TtTERT, including Q168, F178 and W187 (51), and
W187 has been identiﬁed as a bona ﬁde protein contact
with telomeric DNA (52). With respect to human
telomerase, hTERT(1–300) and (1–350) expressed in
reticulocyte lysates can be captured onto biotinylated
telomeric DNA [(55), D.C.F. Sealey and L.A.
Harrington unpublished results]. The capture of hTERT
in this assay is reduced upon removal or mutation of the
N-terminus (55). Previous EMSA studies demonstrated an
ability of puriﬁed ciliate telomerase to bind speciﬁcally to
telomeric DNA; in this context, telomere DNA binding
was TR-dependent (79). To our knowledge, our study rep-
resents the ﬁrst EMSA developed for a speciﬁc fragment
of recombinant telomerase.
Mutations in the N-termini of TERTs have been
identiﬁed that impair the activity of human (55,58–63),
T. thermophila (51,52,80–82) and S. cerevisiae telomerases
(40,54,56,57). We identiﬁed two mutations in hTERT that
attenuated catalytic activity. We targeted hTERT-Q169
for mutation based on the conservation of this residue
with TtTERT-Q168 and the position of the latter on the
ﬂoor of a putative DNA-binding groove on the surface of
the N-terminal domain (51). Like TtTERT-Q168A,
hTERT-Q169A impaired telomerase activity [(51),
Figure 3]; however, unlike TtTERT-Q168A, hTERT-
Q169A did not impair DNA binding [(51,52), Figure 4].
This apparent discrepancy may be due to the diﬀerent
assays employed for studying the DNA interaction.
Jacobs et al. (51) observed that mutation of Q168
reduced the crosslinking of immuno-puriﬁed RRL-
TtTERT to a 20-nt-long iodouracil-substituted telomeric
primer following exposure to UV light and denaturing
PAGE. Romi et al. (52) observed that mutation of Q168
reduced primer aﬃnity in an assay that measured catalytic
activity of RRL-TtTERT following UV-crosslinking to a
6-nt-long iodouracil-substituted telomeric primer. The for-
mation of TERT:DNA crosslinks in these experiments
depends on the proximity of iodouracil to reactive
amino acid side chains. The interaction between hTEN
and an 18-nt-long telomeric primer detected by native
gel EMSA was not subject to these parameters.
Therefore, whereas previous studies have documented
the involvement of TtTERT-Q168 in binding DNA,
we did not ﬁnd similar evidence for hTERT-Q169.
Either there are species-speciﬁc diﬀerences in the
function of this conserved residue, or a role for Q169 in
binding DNA could not be ascertained by analyzing the
behavior of the single amino acid mutant in the native
EMSA. Thus, the phenotype of the hTERT-Q169A
mutation may be similar to that of TtTERT-D94A and
L174A mutations that decrease catalytic activity but not
DNA binding/crosslinking (51).
We also identiﬁed hTERT-Y18 as a residue (at a
non-conserved position but that may lie near the end of
the DNA-binding groove) that is required for normal
catalytic activity but not necessarily DNA binding
(Figures 3 and 4, Supplementary Figure S4). Following
from the discussion above, it is possible that Y18 and
Q169 do not contact DNA. It is also possible that both
Y18 and Q169 contact DNA and can compensate, along
with other DNA-binding residues, for the loss of any one
DNA contact in a DNA-binding assay. The loss of any
one DNA contact may yet render the enzyme incapable of
action on a primer. The contributions of Y18 and Q169 to
the catalytic reaction cycle may be distinct, given that
mutation of each residue impaired activity to a diﬀerent
degree, but the exact contributions of these residues
remain to be determined.
Mutation of hTEN at critical sites interfered with the
ability of telomerase to immortalize human embryonic
kidney cells (Figure 5, Supplementary Figure S5).
Residues H17/Y18/R19 and Q169 were required for the
generation of telomerase activity in cell lysates, as they
were in vitro, and also for telomere length maintenance
and the continued division of cells in culture. We were
not able to formally identify a requirement for Y18 in
extending the replicative lifespan of cells because
transgene expression was lost during propagation of the
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T116A/T117A/S118A triple mutant, which did not
exhibit deﬁcits in DNA binding or activity in vitro
(Figure 4, Table 1), did not regenerate telomerase
activity in cell lysates and did not immortalize cells
(Figure 5, Supplementary Figure S5). Moriarty et al.
showed that an hTERT mutant lacking residues 110–119
displays normal activity in vitro on telomeric primers 18nt
in length (although repeat addition processivity was
reduced on shorter primers), but reduced activity in cell
lysates and an inability to immortalize HA5 cells (62,63).
Collectively, these results suggest that residues 116–118
may interact with cellular factors that inﬂuence
recruitment to the telomere or telomerase activity
in vivo. This possibility is consistent with our prediction
that residues 116–118 may be exposed to the non-DNA-
binding surface of hTEN (Supplementary Figure S4). By
the criteria of Armbruster et al. hTERT(T116A/T117A/
S118A) fulﬁlls the characteristics of a so-called ‘DAT’
mutation that dissociates the in vitro and in vivo activities
of telomerase (60). The human POT1/TPP1 complex,
which interacts with, and can stimulate telomerase, is a
candidate modulator of telomerase in vivo (38,83), but
whether the complex interacts with the N-terminus of
hTERT is not known. Notably, A. thaliana POT1A inter-
acts with telomerase activity in cells and the N-terminus of
AtTERT in vitro (84,85). Several hTERT mutants that
displayed no telomerase activity defect in vitro were not
tested for the ability to immortalize cells (Table 1). It will
be interesting to determine if additional mutations in this
set have a ‘DAT’ phenotype, which might further deﬁne
the residues that are required for the in vivo functions of
telomerase (60).
In addition to binding DNA, hTR and presumably
other cellular factors, the N-terminus of hTERT interacts
with the C-terminal portion of hTERT in complex with
hTR [(59), Figure 3]. Although N- and C-terminal
portions of hTERT each contact hTR, hTR or other
nucleic acids are not required to bridge this interaction
(60,62,86) (Supplementary Figure 3). Co-expression of
the N-terminus of hTERT with the hTERT C-terminus–
hTR complex reconstitutes active telomerase [(59), Figure
3]. There is also evidence to suggest that C-terminal
regions of TERT interact with DNA [(51–53,55,87)
D.C.F. Sealey and L.A. Harrington unpublished results],
and that C-terminal regions are required for normal
telomerase function in vitro and in vivo (58,61,87–89).
Thus, it is possible that N- and C-terminal regions of
TERT combine to form one DNA-binding site.
Alternatively, N- and C-terminal regions of TERT may
bind DNA separately, but in a cooperative manner. In the
latter scenario, the N-terminus of TERT, which has been
described as a low aﬃnity DNA-binding domain (53), may
not recruit telomerase to primers, but once DNA is bound
to another site in hTERT, the local concentration of
DNA available to the N-terminus may be suﬃciently
high for a stable interaction to occur. In turn, the N-
terminus may contribute speciﬁcity (Figure 2), along
with the RNA template in hTR, to the primer sequences
that can be bound and elongated eﬃciently by telomerase.
This hypothesis is consistent with the crosslinking of
E. aediculatus telomerase to primers at both 50- and
30-ends (49), and the observation that telomerase cannot
extend short primers or primers with non-G-rich 50-ends
eﬃciently (44–48,90). Finally, whether the functional
multimerization of N- and C-terminal regions of hTERT
reﬂects an intra- or inter-molecular interaction in the
context of native telomerase remains to be determined.
The exact telomerase reaction mechanism has yet to be
fully elucidated. Structure–function analysis is beginning
to shed light on how various domains of TERT, TR, other
proteins and telomeric DNA associate and work together.
For example, TtTERT-W187 can crosslink to the same
nucleotide in telomeric primers with diﬀerent registers,
suggesting that N-terminus of TERT may form a static
interaction with DNA during each round of RNA
template copying (52). The sequence-speciﬁcity of the
DNA interaction with the N-terminus of hTERT at dif-
ferent nucleotide positions may reﬂect this property
(Figure 2). Also, mutation of TtTERT-L14 impairs
telomere repeat addition processivity but not DNA
binding, which led Zaug et al. (82) to propose models of
how the N-terminus may behave during primer
translocation. These ﬁndings, along with the knowledge
that TtTERT-Q168, the N-terminus of Est2, and now
human TERT-Q169 and Y18 are required for productive
elongation of DNA [(51,52,57), Figure 3], are beginning to
inform an understanding of the molecular events of the
telomerase reaction cycle. Deciphering exactly how the
N-terminus of hTERT enables telomerase function may
provide an additional target for inhibiting telomerase
function in cancer.
NOTE ADDED IN REVISION
While this article was under review, Wyatt et al. (91)
reported that mutation of hTERT-Q169 impairs
telomerase catalytic activity in vitro. The Q169A
mutation did not reduce the interaction of RRL-expressed
hTERT(1–300) with (TTAGGG)3 in a biotinylated DNA
pull-down assay, but did reduce the interaction with (TTA
GGG)2 and TTAGGG primers. Further, hTERT(Q169A)
did not restore telomerase activity, or confer lifespan
extension or telomere maintenance to telomerase-negative
cells. Thus, these ﬁndings are consistent with the present
study.
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